FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285402403> ?p ?o ?g. }

• W4285402403 endingPage "876" @default.
• W4285402403 startingPage "841" @default.
• W4285402403 abstract "More than half of Crohn's disease patients develop intestinal fibrosis-induced intestinal strictures. Elafin is a human protease inhibitor that is down-regulated in the stricturing intestine of Crohn's disease patients. We investigated the efficacy of elafin in reversing intestinal fibrosis and elucidated its mechanism of action.We developed a new method to mimic a stricturing Crohn's disease environment and induce fibrogenesis using stricturing Crohn's disease patient-derived serum exosomes to condition fresh human intestinal tissues and primary stricturing Crohn's disease patient-derived intestinal fibroblasts. Three mouse models of intestinal fibrosis, including SAMP1/YitFc mice, Salmonella-infected mice, and trinitrobenzene sulfonic acid-treated mice, were also studied. Elafin-Eudragit FS30D formulation and elafin-overexpressing construct and lentivirus were used.Elafin reversed collagen synthesis in human intestinal tissues and fibroblasts pretreated with Crohn's disease patient-derived serum exosomes. Proteome arrays identified cathepsin S as a novel fibroblast-derived pro-fibrogenic protease. Elafin directly suppressed cathepsin S activity to inhibit protease-activated receptor 2 activity and Zinc finger E-box-binding homeobox 1 expression, leading to reduced collagen expression in intestinal fibroblasts. Elafin overexpression reversed ileal fibrosis in SAMP1/YitFc mice, cecal fibrosis in Salmonella-infected mice, and colonic fibrosis in trinitrobenzene sulfonic acid-treated mice. Cathepsin S, protease-activated receptor 2 agonist, and zinc finger E-box-binding homeobox 1 overexpression abolished the anti-fibrogenic effect of elafin in fibroblasts and all 3 mouse models of intestinal fibrosis. Oral elafin-Eudragit FS30D treatment abolished colonic fibrosis in trinitrobenzene sulfonic acid-treated mice.Elafin suppresses collagen synthesis in intestinal fibroblasts via cathepsin S-dependent protease-activated receptor 2 inhibition and decreases zinc finger E-box-binding homeobox 1 expression. The reduced collagen synthesis leads to the reversal of intestinal fibrosis. Thus, modified elafin may be a therapeutic approach for intestinal fibrosis." @default.
• W4285402403 created "2022-07-14" @default.
• W4285402403 creator A5002405971 @default.
• W4285402403 creator A5008261139 @default.
• W4285402403 creator A5011213706 @default.
• W4285402403 creator A5012305407 @default.
• W4285402403 creator A5016562362 @default.
• W4285402403 creator A5029901536 @default.
• W4285402403 creator A5034466896 @default.
• W4285402403 creator A5052344334 @default.
• W4285402403 creator A5053448553 @default.
• W4285402403 creator A5072019190 @default.
• W4285402403 creator A5073525946 @default.
• W4285402403 creator A5082605046 @default.
• W4285402403 date "2022-01-01" @default.
• W4285402403 modified "2023-10-14" @default.
• W4285402403 title "Elafin Reverses Intestinal Fibrosis by Inhibiting Cathepsin S-Mediated Protease-Activated Receptor 2" @default.
• W4285402403 cites W1599057242 @default.
• W4285402403 cites W1627442108 @default.
• W4285402403 cites W1804495077 @default.
• W4285402403 cites W1929906891 @default.
• W4285402403 cites W1972225809 @default.
• W4285402403 cites W1984276265 @default.
• W4285402403 cites W1991521290 @default.
• W4285402403 cites W1996139830 @default.
• W4285402403 cites W2005298758 @default.
• W4285402403 cites W2016129079 @default.
• W4285402403 cites W2019851250 @default.
• W4285402403 cites W2033337619 @default.
• W4285402403 cites W2034056147 @default.
• W4285402403 cites W2041243632 @default.
• W4285402403 cites W2052257525 @default.
• W4285402403 cites W2053681311 @default.
• W4285402403 cites W2056478385 @default.
• W4285402403 cites W2062859142 @default.
• W4285402403 cites W2072725822 @default.
• W4285402403 cites W2073878909 @default.
• W4285402403 cites W2087642160 @default.
• W4285402403 cites W2101339759 @default.
• W4285402403 cites W2104523148 @default.
• W4285402403 cites W2112336067 @default.
• W4285402403 cites W2119364523 @default.
• W4285402403 cites W2126769079 @default.
• W4285402403 cites W2128549250 @default.
• W4285402403 cites W2133226723 @default.
• W4285402403 cites W2141926747 @default.
• W4285402403 cites W2156272792 @default.
• W4285402403 cites W2156288459 @default.
• W4285402403 cites W2158050885 @default.
• W4285402403 cites W2169424849 @default.
• W4285402403 cites W222679074 @default.
• W4285402403 cites W2251103812 @default.
• W4285402403 cites W2253256336 @default.
• W4285402403 cites W2254158635 @default.
• W4285402403 cites W2297633672 @default.
• W4285402403 cites W2331857781 @default.
• W4285402403 cites W2467250481 @default.
• W4285402403 cites W2472899497 @default.
• W4285402403 cites W2546645949 @default.
• W4285402403 cites W2593695507 @default.
• W4285402403 cites W2596490556 @default.
• W4285402403 cites W2766468572 @default.
• W4285402403 cites W2768739755 @default.
• W4285402403 cites W2883889243 @default.
• W4285402403 cites W2884423041 @default.
• W4285402403 cites W2890024812 @default.
• W4285402403 cites W2903808022 @default.
• W4285402403 cites W2921851436 @default.
• W4285402403 cites W2944371379 @default.
• W4285402403 cites W2955452369 @default.
• W4285402403 cites W2974147039 @default.
• W4285402403 cites W3026479438 @default.
• W4285402403 cites W3032960251 @default.
• W4285402403 cites W3045638925 @default.
• W4285402403 cites W3128541326 @default.
• W4285402403 cites W3133688564 @default.
• W4285402403 cites W3170979282 @default.
• W4285402403 cites W4211153467 @default.
• W4285402403 doi "https://doi.org/10.1016/j.jcmgh.2022.06.011" @default.
• W4285402403 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35840034" @default.
• W4285402403 hasPublicationYear "2022" @default.
• W4285402403 type Work @default.
• W4285402403 citedByCount "1" @default.
• W4285402403 countsByYear W42854024032023 @default.
• W4285402403 crossrefType "journal-article" @default.
• W4285402403 hasAuthorship W4285402403A5002405971 @default.
• W4285402403 hasAuthorship W4285402403A5008261139 @default.
• W4285402403 hasAuthorship W4285402403A5011213706 @default.
• W4285402403 hasAuthorship W4285402403A5012305407 @default.
• W4285402403 hasAuthorship W4285402403A5016562362 @default.
• W4285402403 hasAuthorship W4285402403A5029901536 @default.
• W4285402403 hasAuthorship W4285402403A5034466896 @default.
• W4285402403 hasAuthorship W4285402403A5052344334 @default.
• W4285402403 hasAuthorship W4285402403A5053448553 @default.
• W4285402403 hasAuthorship W4285402403A5072019190 @default.
• W4285402403 hasAuthorship W4285402403A5073525946 @default.
• W4285402403 hasAuthorship W4285402403A5082605046 @default.
• W4285402403 hasBestOaLocation W42854024031 @default.

• next